Checkpoint Therapeutics Inc. (NASDAQ: CKPT)
$2.67
+0.1550 ( +6.17% ) 621.9K
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in theĀ USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Market Data
Open
$2.67
Previous close
$2.51
Volume
621.9K
Market cap
$102.06M
Day range
$2.46 - $2.71
52 week range
$1.30 - $3.62
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Mar 22, 2024 |
3 | Insider transactions | 2 | Mar 19, 2024 |
8-k | 8K-related | 15 | Mar 18, 2024 |
4 | Insider transactions | 1 | Mar 01, 2024 |
4 | Insider transactions | 1 | Mar 01, 2024 |
4 | Insider transactions | 1 | Feb 02, 2024 |
5 | Other | 1 | Feb 02, 2024 |
8-k | 8K-related | 14 | Feb 02, 2024 |
4 | Insider transactions | 1 | Feb 02, 2024 |
8-k | 8K-related | 22 | Jan 30, 2024 |